A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics made a pivotal discovery in the field ...

The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...

Junior guard Audrey Baxter lost her mom to acute myeloid leukemia last March. “I don’t know a lot of people that would be ...

The analysis found that less than fifty percent of enrolled patients deceased after the median follow-up period of 13.5 months, indicating a median survival of over 13.5 Months in the trial vs.

Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC) Recommended Continuation of the Clinical Trial Without Modification – - Based on a Review of ...

A phase 3 trial confirms “the potent anti-leukemic effect” of consolidation with allogeneic transplant in older patients with acute myeloid leukemia, according to researchers.